Is AbbVie a Bad News Buy?

·4 min read

The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting